Screener
Adaptive Biotechnologies ADPT Q2 2026 earnings
Reported July 28, 2026 · After market close
Revenue$71.6MBeat by $6.1M
EPS-$0.25Miss by $0.12
Revenue estimate$65.4M
EPS estimate-$0.13
“The combination of our operating performance, fortified balance sheet and plan to separate the Immune Medicine business enhances our ability to create long-term value for our shareholders.”
Next report
Nov 4, 2026 (in 2 months)Revenue estimate$71.6M
EPS estimate-$0.10
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Adaptive Biotechnologies report Q2 2026 earnings?
- Adaptive Biotechnologies (ADPT) reported Q2 2026 earnings on July 28, 2026 after market close.
- What were Adaptive Biotechnologies's Q2 2026 revenue and EPS?
- Adaptive Biotechnologies reported revenue of $71.6M and eps of $-0.25 for Q2 2026.
- Did Adaptive Biotechnologies beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $65.4M by $6.1M. EPS missed the consensus estimate of $-0.13 by $0.12.
- How did Adaptive Biotechnologies's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 21.5% from $58.9M a year earlier and eps declined 47.1% from $-0.17.
- Where can I find Adaptive Biotechnologies's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001193125-26-323753) and the 10-Q periodic report (0001193125-26-332940) directly on SEC EDGAR. The filing index links above go to sec.gov.
